Company Description
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jul 19, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Fred Aslan |
Contact Details
Address: 5505 Morehouse Drive, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 267 4467 |
| Website | artivabio.com |
Stock Details
| Ticker Symbol | ARTV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 1817241 |
| ISIN Number | US04317A1079 |
| Employer ID | 86-3614316 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Fred Aslan M.D. | President, Chief Executive Officer and Director |
| Dr. Peter Flynn Ph.D. | Co-Founder and Strategic Advisor |
| Thad Huston C.M.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 10, 2026 | 10-K | Annual Report |
| Mar 10, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 8-K | Current Report |
| Dec 15, 2025 | 144 | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Nov 17, 2025 | 144 | Filing |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 10-Q | Quarterly Report |